A detailed history of Susquehanna International Group, LLP transactions in Incyte Corp stock. As of the latest transaction made, Susquehanna International Group, LLP holds 161,971 shares of INCY stock, worth $11.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
161,971
Previous 108,634 49.1%
Holding current value
$11.2 Million
Previous $6.59 Million 62.58%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$57.33 - $68.61 $3.06 Million - $3.66 Million
53,337 Added 49.1%
161,971 $10.7 Million
Q2 2024

Aug 15, 2024

SELL
$51.18 - $63.75 $4.2 Million - $5.23 Million
-82,046 Reduced 43.03%
108,634 $6.59 Million
Q1 2024

May 07, 2024

BUY
$56.55 - $66.59 $6.77 Million - $7.97 Million
119,639 Added 168.41%
190,680 $10.9 Million
Q4 2023

Feb 14, 2024

SELL
$52.16 - $64.19 $1.68 Million - $2.06 Million
-32,118 Reduced 31.13%
71,041 $4.46 Million
Q3 2023

Nov 14, 2023

BUY
$57.77 - $65.93 $338,070 - $385,822
5,852 Added 6.01%
103,159 $5.96 Million
Q2 2023

Aug 11, 2023

SELL
$60.95 - $75.51 $1.57 Million - $1.95 Million
-25,773 Reduced 20.94%
97,307 $6.06 Million
Q1 2023

May 16, 2023

BUY
$70.23 - $86.01 $3.16 Million - $3.87 Million
44,996 Added 57.63%
123,080 $8.89 Million
Q4 2022

Feb 14, 2023

SELL
$67.18 - $84.11 $7.92 Million - $9.92 Million
-117,915 Reduced 60.16%
78,084 $6.27 Million
Q3 2022

Nov 14, 2022

BUY
$66.18 - $82.86 $9.84 Million - $12.3 Million
148,637 Added 313.83%
195,999 $13.1 Million
Q2 2022

Aug 15, 2022

SELL
$66.18 - $83.18 $2.67 Million - $3.36 Million
-40,339 Reduced 46.0%
47,362 $3.6 Million
Q1 2022

May 16, 2022

SELL
$66.02 - $79.71 $11.7 Million - $14.1 Million
-177,223 Reduced 66.9%
87,701 $6.97 Million
Q4 2021

Feb 14, 2022

BUY
$63.34 - $74.11 $5.31 Million - $6.21 Million
83,814 Added 46.28%
264,924 $19.4 Million
Q3 2021

Nov 15, 2021

BUY
$68.67 - $84.02 $2.33 Million - $2.85 Million
33,893 Added 23.02%
181,110 $12.5 Million
Q2 2021

Aug 11, 2021

BUY
$79.87 - $87.53 $1.31 Million - $1.43 Million
16,375 Added 12.52%
147,217 $12.4 Million
Q1 2021

May 17, 2021

BUY
$76.02 - $100.5 $4.24 Million - $5.6 Million
55,738 Added 74.21%
130,842 $10.6 Million
Q4 2020

Feb 16, 2021

BUY
$80.74 - $97.7 $4.27 Million - $5.16 Million
52,830 Added 237.18%
75,104 $6.53 Million
Q3 2020

Nov 16, 2020

SELL
$85.07 - $109.69 $7.48 Million - $9.65 Million
-87,930 Reduced 79.79%
22,274 $2 Million
Q2 2020

Aug 14, 2020

SELL
$74.18 - $108.93 $796,619 - $1.17 Million
-10,739 Reduced 8.88%
110,204 $11.5 Million
Q1 2020

May 15, 2020

SELL
$63.18 - $85.97 $1.17 Million - $1.59 Million
-18,469 Reduced 13.25%
120,943 $8.86 Million
Q4 2019

Feb 14, 2020

SELL
$73.04 - $95.72 $3.6 Million - $4.72 Million
-49,272 Reduced 26.11%
139,412 $12.2 Million
Q3 2019

Nov 14, 2019

BUY
$72.82 - $86.52 $158,456 - $188,267
2,176 Added 1.17%
188,684 $14 Million
Q2 2019

Aug 16, 2019

BUY
$73.52 - $88.7 $2.44 Million - $2.94 Million
33,157 Added 21.62%
186,508 $15.8 Million
Q2 2019

Aug 14, 2019

BUY
$73.52 - $88.7 $11.1 Million - $13.4 Million
150,597 Added 5468.3%
153,351 $13 Million
Q1 2019

May 15, 2019

SELL
$63.56 - $88.17 $7.58 Million - $10.5 Million
-119,183 Reduced 97.74%
2,754 $237,000
Q4 2018

Feb 14, 2019

SELL
$58.5 - $69.94 $878,494 - $1.05 Million
-15,017 Reduced 10.96%
121,937 $7.75 Million
Q3 2018

Nov 14, 2018

BUY
$61.75 - $74.23 $67,307 - $80,910
1,090 Added 0.8%
136,954 $9.46 Million
Q2 2018

Aug 14, 2018

BUY
$60.85 - $83.98 $2.67 Million - $3.69 Million
43,922 Added 47.77%
135,864 $9.1 Million
Q1 2018

May 15, 2018

BUY
$83.06 - $100.98 $1.37 Million - $1.67 Million
16,491 Added 21.86%
91,942 $7.66 Million
Q4 2017

Feb 14, 2018

BUY
$93.56 - $116.6 $7.06 Million - $8.8 Million
75,451
75,451 $7.15 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.4B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.